Trending: Lilly Anti-Obesity Drug Tirzepatide Reduces Sleep Apnea Severity in Studies
Provided by
Dow Jones
14:04 -- Eli Lilly is one of the most mentioned companies in the U.S. across all news items in the past 12 hours, according to Factiva data. The company's anti-obesity drug tirzepatide, sold as Zepbound in the U.S., reduced obstructive sleep apnea severity in Phase 3 clinical trials. The company said Friday that results showed a significant proportion of patients with moderate-to-severe OSA and obesity treated with tirzepatide achieved disease resolution. Lilly shares were recently up 1.6% to $898.16. Dow Jones & Co. owns Factiva. (josh.beckerman@wsj.com).
(END) Dow Jones Newswires
June 24, 2024 14:19 ET (18:19 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Q3 2024 Stock Market Outlook: Is the AI Stock Trade Over?
-
Ian Bremmer: 4 Big Geopolitical Risks to Watch
-
What’s Happening In the Markets This Week
-
Obesity Drug Stocks: Why It Will Be ‘Exceptionally Difficult’ to Dethrone Eli Lilly and Novo Nordisk
-
What Does Chipotle’s Stock Split Mean for Investors?
-
5 Stocks to Buy Before the Fed Cuts Interest Rates in 2024
-
Markets Brief: Inflation Is Back In the Spotlight
-
What a Strong Economy Now Means for the Rest of 2024
-
10 Top Dividend Stocks for 2024
-
Finding Small-Cap Stock Opportunities In a Big-Cap World
-
The 10 Best Companies to Invest in Now
-
Nike Earnings: Dim Sales Outlook Slams Shares, but Patient Investors Could Be Rewarded
-
2 Top E-Commerce Stock Picks
-
Our Top Pick for Investing in US Renewable Energy
-
Micron Earnings: We Raise Our DRAM Forecast and Valuation Behind Stronger Pricing Assumptions
-
10 Undervalued Wide-Moat Stocks